$EHC
Encompass Health Corp

2012 Q2 Form 10-Q Financial Statement

#000078516112000039 Filed on July 27, 2012

View on sec.gov

Income Statement

Concept 2012 Q2 2011 Q2
Revenue $533.4M $505.1M
YoY Change 5.6% 8.09%
Cost Of Revenue $25.90M $26.20M
YoY Change -1.15% 4.8%
Gross Profit $501.0M $473.9M
YoY Change 5.72% 7.14%
Gross Profit Margin 93.93% 93.82%
Selling, General & Admin $303.2M $289.5M
YoY Change 4.73% 5.46%
% of Gross Profit 60.52% 61.09%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $20.00M $19.60M
YoY Change 2.04% 15.29%
% of Gross Profit 3.99% 4.14%
Operating Expenses $397.6M $384.5M
YoY Change 3.41% 5.89%
Operating Profit $103.4M $89.40M
YoY Change 15.66% 12.88%
Interest Expense -$19.90M -$31.70M
YoY Change -37.22% 16.54%
% of Operating Profit -19.25% -35.46%
Other Income/Expense, Net $400.0K $700.0K
YoY Change -42.86% -50.0%
Pretax Income $83.30M $41.90M
YoY Change 98.81% -20.79%
Income Tax $26.90M $11.20M
% Of Pretax Income 32.29% 26.73%
Net Earnings $46.70M $21.90M
YoY Change 113.24% -53.7%
Net Earnings / Revenue 8.76% 4.34%
Basic Earnings Per Share $0.42 $0.16
Diluted Earnings Per Share $0.42 $0.17
COMMON SHARES
Basic Shares Outstanding 94.60M shares 93.30M shares
Diluted Shares Outstanding 108.0M shares 109.5M shares

Balance Sheet

Concept 2012 Q2 2011 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $41.10M $60.30M
YoY Change -31.84% -65.06%
Cash & Equivalents $41.10M $60.30M
Short-Term Investments
Other Short-Term Assets $137.7M $155.4M
YoY Change -11.39% 45.92%
Inventory
Prepaid Expenses
Receivables $245.7M $212.8M
Other Receivables $0.00 $0.00
Total Short-Term Assets $424.5M $428.5M
YoY Change -0.93% -14.96%
LONG-TERM ASSETS
Property, Plant & Equipment $718.9M $642.5M
YoY Change 11.89% -3.31%
Goodwill $421.7M
YoY Change
Intangibles $69.00M
YoY Change
Long-Term Investments
YoY Change
Other Assets $128.8M $841.0M
YoY Change -84.68% 762.56%
Total Long-Term Assets $1.891B $1.949B
YoY Change -2.96% 55.64%
TOTAL ASSETS
Total Short-Term Assets $424.5M $428.5M
Total Long-Term Assets $1.891B $1.949B
Total Assets $2.316B $2.377B
YoY Change -2.6% 35.38%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $59.60M $45.40M
YoY Change 31.28% -4.02%
Accrued Expenses $265.0M $273.7M
YoY Change -3.18% -15.16%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $324.6M $319.1M
YoY Change 1.72% -18.47%
LONG-TERM LIABILITIES
Long-Term Debt $1.219B $1.440B
YoY Change -15.33% -11.81%
Other Long-Term Liabilities $135.8M $134.2M
YoY Change 1.19% -16.96%
Total Long-Term Liabilities $1.355B $1.574B
YoY Change -13.92% -12.28%
TOTAL LIABILITIES
Total Short-Term Liabilities $324.6M $319.1M
Total Long-Term Liabilities $1.355B $1.574B
Total Liabilities $1.680B $1.977B
YoY Change -15.01% -12.74%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $195.8M $400.9M
YoY Change
Total Liabilities & Shareholders Equity $2.316B $2.377B
YoY Change -2.6% 35.38%

Cashflow Statement

Concept 2012 Q2 2011 Q2
OPERATING ACTIVITIES
Net Income $46.70M $21.90M
YoY Change 113.24% -53.7%
Depreciation, Depletion And Amortization $20.00M $19.60M
YoY Change 2.04% 15.29%
Cash From Operating Activities $114.0M $68.60M
YoY Change 66.18% -22.31%
INVESTING ACTIVITIES
Capital Expenditures -$60.30M -$20.50M
YoY Change 194.15% 35.76%
Acquisitions $2.100M
YoY Change
Other Investing Activities $4.900M -$5.300M
YoY Change -192.45% -541.67%
Cash From Investing Activities -$55.40M -$25.80M
YoY Change 114.73% 85.61%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -61.80M -123.5M
YoY Change -49.96% 560.43%
NET CHANGE
Cash From Operating Activities 114.0M 68.60M
Cash From Investing Activities -55.40M -25.80M
Cash From Financing Activities -61.80M -123.5M
Net Change In Cash -3.200M -80.70M
YoY Change -96.03% -244.88%
FREE CASH FLOW
Cash From Operating Activities $114.0M $68.60M
Capital Expenditures -$60.30M -$20.50M
Free Cash Flow $174.3M $89.10M
YoY Change 95.62% -13.83%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2012Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
59600000 USD
CY2011Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
45400000 USD
CY2011Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
222800000 USD
CY2012Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
245700000 USD
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
12000000 USD
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9500000 USD
us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
81400000 USD
us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
53400000 USD
CY2012Q2 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
24600000 USD
CY2011Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
21400000 USD
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1100000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1800000 shares
CY2012Q2 us-gaap Assets
Assets
2315700000 USD
CY2011Q4 us-gaap Assets
Assets
2271200000 USD
CY2011Q4 us-gaap Assets Current
AssetsCurrent
391000000 USD
CY2012Q2 us-gaap Assets Current
AssetsCurrent
424500000 USD
us-gaap Capitalized Computer Software Additions
CapitalizedComputerSoftwareAdditions
-3800000 USD
us-gaap Capitalized Computer Software Additions
CapitalizedComputerSoftwareAdditions
-11600000 USD
CY2012Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
41100000 USD
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
30100000 USD
CY2011Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
60300000 USD
CY2010Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
48300000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
11900000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
11100000 USD
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
0.82
us-gaap Cash Provided By Used In Investing Activities Discontinued Operations
CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
7700000 USD
us-gaap Cash Provided By Used In Investing Activities Discontinued Operations
CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
-300000 USD
us-gaap Cash Provided By Used In Operating Activities Discontinued Operations
CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
7200000 USD
us-gaap Cash Provided By Used In Operating Activities Discontinued Operations
CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
1700000 USD
CY2012Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2011Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
102100000 USD
CY2011Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
22100000 USD
CY2012Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
46900000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
91900000 USD
CY2011Q2 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
10400000 USD
us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
25800000 USD
CY2012Q2 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
13200000 USD
us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
22100000 USD
CY2012Q2 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
60100000 USD
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
124200000 USD
CY2011Q2 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
32500000 USD
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
117700000 USD
CY2012Q2 us-gaap Costs And Expenses
CostsAndExpenses
424100000 USD
CY2011Q2 us-gaap Costs And Expenses
CostsAndExpenses
401100000 USD
us-gaap Costs And Expenses
CostsAndExpenses
803700000 USD
us-gaap Costs And Expenses
CostsAndExpenses
851000000 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
5200000 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
51700000 USD
CY2012Q2 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
579300000 USD
CY2012Q2 us-gaap Deferred Tax Assets Net Current
DeferredTaxAssetsNetCurrent
26500000 USD
CY2012Q2 us-gaap Deferred Tax Assets Net Noncurrent
DeferredTaxAssetsNetNoncurrent
552800000 USD
CY2011Q4 us-gaap Deferred Tax Assets Net Noncurrent
DeferredTaxAssetsNetNoncurrent
608100000 USD
CY2012Q2 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
50000000 USD
CY2011Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
19600000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
39100000 USD
CY2012Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
20000000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
39500000 USD
CY2012Q2 us-gaap Dividends Preferred Stock
DividendsPreferredStock
6000000 USD
us-gaap Dividends Preferred Stock
DividendsPreferredStock
12400000 USD
us-gaap Dividends Preferred Stock
DividendsPreferredStock
13000000 USD
CY2011Q2 us-gaap Dividends Preferred Stock
DividendsPreferredStock
6500000 USD
us-gaap Dividends Preferred Stock Cash
DividendsPreferredStockCash
12400000 USD
us-gaap Dividends Preferred Stock Cash
DividendsPreferredStockCash
13000000 USD
CY2011Q4 us-gaap Due From Related Parties Noncurrent
DueFromRelatedPartiesNoncurrent
0 USD
CY2012Q2 us-gaap Due From Related Parties Noncurrent
DueFromRelatedPartiesNoncurrent
0 USD
CY2011Q4 us-gaap Due To Related Parties Noncurrent
DueToRelatedPartiesNoncurrent
0 USD
CY2012Q2 us-gaap Due To Related Parties Noncurrent
DueToRelatedPartiesNoncurrent
0 USD
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
0.95
CY2012Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
0.43
CY2011Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
0.17
us-gaap Equity Method Investment Dividends Or Distributions
EquityMethodInvestmentDividendsOrDistributions
5500000 USD
us-gaap Equity Method Investment Dividends Or Distributions
EquityMethodInvestmentDividendsOrDistributions
5500000 USD
CY2012Q2 us-gaap Equity Method Investment Summarized Financial Information Income Loss From Continuing Operations Before Extraordinary Items
EquityMethodInvestmentSummarizedFinancialInformationIncomeLossFromContinuingOperationsBeforeExtraordinaryItems
6900000 USD
us-gaap Equity Method Investment Summarized Financial Information Income Loss From Continuing Operations Before Extraordinary Items
EquityMethodInvestmentSummarizedFinancialInformationIncomeLossFromContinuingOperationsBeforeExtraordinaryItems
12600000 USD
us-gaap Equity Method Investment Summarized Financial Information Income Loss From Continuing Operations Before Extraordinary Items
EquityMethodInvestmentSummarizedFinancialInformationIncomeLossFromContinuingOperationsBeforeExtraordinaryItems
14400000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
58000000 USD
CY2012Q2 us-gaap Goodwill
Goodwill
421700000 USD
CY2011Q4 us-gaap Goodwill
Goodwill
421700000 USD
CY2012Q2 us-gaap Guarantee Obligations Maximum Exposure
GuaranteeObligationsMaximumExposure
20500000 USD
CY2011Q2 us-gaap Equity Method Investment Summarized Financial Information Income Loss From Continuing Operations Before Extraordinary Items
EquityMethodInvestmentSummarizedFinancialInformationIncomeLossFromContinuingOperationsBeforeExtraordinaryItems
7000000 USD
us-gaap Equity Method Investment Summarized Financial Information Net Income Loss
EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss
14400000 USD
CY2011Q2 us-gaap Equity Method Investment Summarized Financial Information Net Income Loss
EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss
7000000 USD
CY2012Q2 us-gaap Equity Method Investment Summarized Financial Information Net Income Loss
EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss
6900000 USD
us-gaap Equity Method Investment Summarized Financial Information Net Income Loss
EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss
12600000 USD
CY2012Q2 us-gaap Equity Method Investment Summarized Financial Information Revenue
EquityMethodInvestmentSummarizedFinancialInformationRevenue
22600000 USD
us-gaap Equity Method Investment Summarized Financial Information Revenue
EquityMethodInvestmentSummarizedFinancialInformationRevenue
41600000 USD
us-gaap Equity Method Investment Summarized Financial Information Revenue
EquityMethodInvestmentSummarizedFinancialInformationRevenue
45600000 USD
CY2011Q2 us-gaap Equity Method Investment Summarized Financial Information Revenue
EquityMethodInvestmentSummarizedFinancialInformationRevenue
21200000 USD
CY2012Q2 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-600000 USD
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-1400000 USD
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-1100000 USD
CY2011Q2 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-1000000 USD
CY2012Q2 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 USD
CY2011Q2 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-26100000 USD
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-26100000 USD
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 USD
CY2012Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
28000000 USD
CY2011Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
27400000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
54300000 USD
us-gaap Health Care Organization Revenue
HealthCareOrganizationRevenue
1011100000 USD
us-gaap Health Care Organization Revenue
HealthCareOrganizationRevenue
1072000000 USD
CY2012Q2 us-gaap Health Care Organization Revenue
HealthCareOrganizationRevenue
533400000 USD
CY2011Q2 us-gaap Health Care Organization Revenue
HealthCareOrganizationRevenue
505100000 USD
us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
1300000 USD
CY2012Q2 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
43200000 USD
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
87800000 USD
CY2011Q2 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
19400000 USD
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
81600000 USD
us-gaap Income Loss From Continuing Operations Attributable To Noncontrolling Entity
IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity
25800000 USD
CY2012Q2 us-gaap Income Loss From Continuing Operations Attributable To Noncontrolling Entity
IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity
13200000 USD
us-gaap Income Loss From Continuing Operations Attributable To Noncontrolling Entity
IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity
23100000 USD
CY2011Q2 us-gaap Income Loss From Continuing Operations Attributable To Noncontrolling Entity
IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity
11300000 USD
CY2012Q2 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
56400000 USD
us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
104700000 USD
CY2011Q2 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
30700000 USD
us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
113600000 USD
us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
0.79
CY2012Q2 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
0.39
us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
0.74
CY2011Q2 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
0.14
CY2011Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
1600000 USD
CY2012Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
3500000 USD
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
19100000 USD
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
3100000 USD
us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
20100000 USD
us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
3100000 USD
CY2011Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
2500000 USD
CY2012Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
3500000 USD
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare
0.21
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare
0.03
CY2011Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare
0.03
CY2012Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare
0.04
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
5700000 USD
CY2011Q2 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
3200000 USD
CY2012Q2 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
3100000 USD
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
6400000 USD
CY2011Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
11200000 USD
CY2012Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
26900000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
56000000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3800000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
10300000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
800000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
15900000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
35700000 USD
us-gaap Increase Decrease In Accrued Salaries
IncreaseDecreaseInAccruedSalaries
-15800000 USD
us-gaap Increase Decrease In Accrued Salaries
IncreaseDecreaseInAccruedSalaries
4300000 USD
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
7000000 USD
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
12300000 USD
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
5500000 USD
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
11500000 USD
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
-5300000 USD
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
-4600000 USD
us-gaap Incremental Common Shares Attributable To Conversion Of Preferred Stock
IncrementalCommonSharesAttributableToConversionOfPreferredStock
12500000 shares
CY2012Q2 us-gaap Incremental Common Shares Attributable To Conversion Of Preferred Stock
IncrementalCommonSharesAttributableToConversionOfPreferredStock
12000000 shares
CY2011Q2 us-gaap Incremental Common Shares Attributable To Conversion Of Preferred Stock
IncrementalCommonSharesAttributableToConversionOfPreferredStock
13100000 shares
us-gaap Incremental Common Shares Attributable To Conversion Of Preferred Stock
IncrementalCommonSharesAttributableToConversionOfPreferredStock
13100000 shares
CY2011Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
57700000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1000000 USD
dei Entity Voluntary Filers
EntityVoluntaryFilers
No
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
900000 USD
CY2012Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
69000000 USD
CY2011Q2 us-gaap Interest And Debt Expense
InterestAndDebtExpense
34900000 USD
CY2012Q2 us-gaap Interest And Debt Expense
InterestAndDebtExpense
23000000 USD
us-gaap Interest And Debt Expense
InterestAndDebtExpense
70000000 USD
us-gaap Interest And Debt Expense
InterestAndDebtExpense
46300000 USD
CY2012Q2 us-gaap Investments In Affiliates Subsidiaries Associates And Joint Ventures
InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
29500000 USD
CY2011Q4 us-gaap Investments In Affiliates Subsidiaries Associates And Joint Ventures
InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
29000000 USD
CY2011Q4 us-gaap Liabilities
Liabilities
1682200000 USD
CY2012Q2 us-gaap Liabilities
Liabilities
1679800000 USD
CY2011Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2271200000 USD
CY2012Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2315700000 USD
CY2012Q2 us-gaap Liabilities Current
LiabilitiesCurrent
324600000 USD
CY2011Q4 us-gaap Liabilities Current
LiabilitiesCurrent
313200000 USD
CY2011Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1235800000 USD
CY2012Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1219400000 USD
us-gaap Loss Contingency Disclosures
LossContingencyDisclosures
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Contingencies</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We operate in a highly regulated and litigious industry. As a result, various lawsuits, claims, and legal and regulatory proceedings have been and can be expected to be instituted or asserted against us. The resolution of any such lawsuits, claims, or legal and regulatory proceedings could materially and adversely affect our financial position, results of operations, and cash flows in a given period.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Derivative Litigation&#8212;</font></div><div style="line-height:120%;padding-bottom:13px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All lawsuits purporting to be derivative complaints filed in the Circuit Court of Jefferson County, Alabama since 2002 have been consolidated and stayed in favor of the first-filed action captioned </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Tucker v. Scrushy</font><font style="font-family:inherit;font-size:10pt;"> and filed August&#160;28, 2002. Derivative lawsuits in other jurisdictions have been stayed. The </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Tucker</font><font style="font-family:inherit;font-size:10pt;"> complaint asserted claims on our behalf against, among others, a number of our former officers and directors and Ernst&#160;&amp; Young LLP, our former auditor. When originally filed, the primary allegations in the </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Tucker</font><font style="font-family:inherit;font-size:10pt;"> case involved self-dealing by Richard M. Scrushy, our former chairman and chief executive officer, and other insiders through transactions with various entities allegedly controlled by Mr.&#160;Scrushy. The complaint was amended four times to add additional defendants and include claims of accounting fraud, improper Medicare billing practices, and additional self-dealing transactions. The </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Tucker</font><font style="font-family:inherit;font-size:10pt;"> derivative litigation, including a </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$2.9 billion</font><font style="font-family:inherit;font-size:10pt;"> judgment against Mr. Scrushy, and the related settlements to date are more fully described in &#8220;Litigation By and Against Richard M. Scrushy&#8221; and &#8220;Litigation By and Against Former Independent Auditor&#8221; below and in Note 21, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Settlements</font><font style="font-family:inherit;font-size:10pt;">, &#8220;UBS Litigation Settlement,&#8221; and Note 22, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Contingencies and Other Commitments</font><font style="font-family:inherit;font-size:10pt;">, to the consolidated financial statements accompanying the 2011 Form 10-K.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Litigation By and Against Richard M. Scrushy&#8212; </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December&#160;9, 2005, Mr.&#160;Scrushy filed a complaint in the Circuit Court of Jefferson County, Alabama, captioned </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Scrushy v. HealthSouth</font><font style="font-family:inherit;font-size:10pt;">. The complaint alleged that, as a result of Mr.&#160;Scrushy&#8217;s removal from the position of chief executive officer in March 2003, we owed him &#8220;</font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">in excess of $70 million</font><font style="font-family:inherit;font-size:10pt;">&#8221; pursuant to an employment agreement dated as of September&#160;17, 2002. On December 28, 2005, we counterclaimed against Mr. Scrushy, asserting claims for breaches of fiduciary duty and fraud arising out of Mr. Scrushy&#8217;s tenure with us, and seeking compensatory damages, punitive damages, and disgorgement of wrongfully obtained benefits. We also asserted that any employment agreements with Mr. Scrushy should be void and unenforceable. On July 7, 2009, we filed a motion for summary judgment on all claims by Mr. Scrushy based upon the </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Tucker</font><font style="font-family:inherit;font-size:10pt;"> court&#8217;s June 18, 2009 ruling that Mr. Scrushy&#8217;s employment agreements are void and rescinded.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 18, 2009, the Circuit Court of Jefferson County, Alabama ruled on our derivative claims against Mr. Scrushy presented during a non-jury trial held May 11 to May 26, 2009. The court held Mr. Scrushy responsible for fraud and breach of fiduciary duties and awarded us </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$2.9 billion</font><font style="font-family:inherit;font-size:10pt;"> in damages. On July 24, 2009, Mr. Scrushy filed a notice of appeal of the trial court&#8217;s decision, and the parties subsequently submitted their briefs to the Supreme Court of Alabama. On January 28, 2011, the Supreme Court upheld the trial court&#8217;s decision in its entirety. On April 15, 2011, the Alabama Supreme Court denied Mr. Scrushy's application for a rehearing of its initial decision. On September 2, 2011, we renewed our prior motion for summary judgment on all claims by Mr. Scrushy based on the Alabama Supreme Court's ruling. On March 5, 2012, the court conditionally granted summary judgment in our favor, and that has since become final.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We will pursue collection aggressively and to the fullest extent permitted by law. We, in coordination with derivative plaintiffs' counsel, are attempting to locate, in order to collect the judgment, Mr. Scrushy's current assets and other assets we believe were improperly disposed. Part of this effort is a fraudulent transfer complaint filed on July&#160;2, 2009 against Mr. Scrushy and a number of related entities by derivative plaintiffs for the benefit of HealthSouth in the Circuit Court of Jefferson County, Alabama, captioned </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Tucker v. Scrushy et al</font><font style="font-family:inherit;font-size:10pt;">. While these collection efforts continue, some of Mr. Scrushy&#8217;s assets have been seized and sold at auction pursuant to the state law procedure for collection of a judgment. Other assets will likewise be sold from time to time. On May 3, 2011, the Circuit Court of Jefferson County entered an order for distribution of amounts collected and liquidated. After reimbursement of reasonable out-of-pocket expenses incurred by HealthSouth and the attorneys for the derivative shareholder plaintiffs for property maintenance of and fees incurred to locate Mr. Scrushy's assets and after recording a liability for the federal plaintiffs' </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">25%</font><font style="font-family:inherit;font-size:10pt;"> apportionment of any net recovery from Mr. Scrushy as required in our consolidated securities action settlement, we recorded a </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$12.3 million</font><font style="font-family:inherit;font-size:10pt;"> net gain in </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Government, class action, and related settlements</font><font style="font-family:inherit;font-size:10pt;"> in our consolidated statement of operations for the year ended December 31, 2011 in connection with our receipt of cash distributions. For further discussion of our consolidated securities action settlement that previously resolved claims brought against us by former stockholders and bondholders, see Note 21, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Settlements</font><font style="font-family:inherit;font-size:10pt;">, "Securities Litigation Settlement" to the consolidated financial statements accompanying the 2011 Form 10-K. We are obligated to pay </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">35%</font><font style="font-family:inherit;font-size:10pt;"> of any recovery from Mr. Scrushy along with reasonable out-of-pocket expenses to the attorneys for the derivative shareholder plaintiffs. In connection with those obligations, during 2011, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$5.2 million</font><font style="font-family:inherit;font-size:10pt;"> of the amounts previously collected were distributed to attorneys for the derivative shareholder plaintiffs. We recorded this cash distribution as part of </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Professional fees&#8212;accounting, tax, and legal</font><font style="font-family:inherit;font-size:10pt;"> in our consolidated statement of operations for the year ended December&#160;31, 2011.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Litigation By and Against Former Independent Auditor&#8212;</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2003, claims on behalf of HealthSouth were brought in the </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Tucker</font><font style="font-family:inherit;font-size:10pt;"> derivative litigation against Ernst &amp; Young, alleging that from 1996 through 2002, when Ernst &amp; Young served as our independent auditor, Ernst &amp; Young acted recklessly and with gross negligence in performing its duties, and specifically that Ernst &amp; Young failed to perform reviews and audits of our financial statements with due professional care as required by law and by its contractual agreements with us. The claims further allege Ernst &amp; Young either knew of or, in the exercise of due care, should have discovered and investigated the fraudulent and improper accounting practices being directed by certain officers and employees, and should have reported them to our board of directors and the audit committee. The claims seek compensatory and punitive damages, disgorgement of fees received from us by Ernst &amp; Young, and attorneys&#8217; fees and costs. On March&#160;18, 2005, Ernst&#160;&amp; Young filed a lawsuit captioned </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Ernst&#160;&amp; Young LLP v. HealthSouth Corp.</font><font style="font-family:inherit;font-size:10pt;"> in the Circuit Court of Jefferson County, Alabama. The complaint alleges we provided Ernst&#160;&amp; Young with fraudulent management representation letters, financial statements, invoices, bank reconciliations, and journal entries in an effort to conceal accounting fraud. Ernst&#160;&amp; Young claims that as a result of our actions, Ernst&#160;&amp; Young&#8217;s reputation has been injured and it has and will incur damages, expenses, and legal fees. On April&#160;1, 2005, we answered Ernst&#160;&amp; Young&#8217;s claims and asserted counterclaims related or identical to those asserted in the </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Tucker</font><font style="font-family:inherit;font-size:10pt;"> action. Upon Ernst&#160;&amp; Young&#8217;s motion, the Alabama state court referred Ernst&#160;&amp; Young&#8217;s claims and our counterclaims to arbitration pursuant to a clause in the engagement agreements between HealthSouth and Ernst &amp; Young. On July&#160;12, 2006, we and the derivative plaintiffs filed an arbitration demand on behalf of HealthSouth against Ernst&#160;&amp; Young. On August&#160;7, 2006, Ernst &amp; Young filed an answering statement and counterclaim in the arbitration reasserting the claims made in state court. In August 2006, we and the derivative plaintiffs agreed to jointly prosecute the claims against Ernst &amp; Young in arbitration.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are vigorously pursuing our claims against Ernst &amp; Young and defending the claims against us. The three-person arbitration panel that is adjudicating the claims and counterclaims in arbitration was selected under rules of the American Arbitration Association (the "AAA"). The trial phase of the arbitration process began on July 12, 2010 and is continuing as schedules permit. However, pursuant to an order of the AAA panel, all aspects of the arbitration are confidential. Accordingly, we will not discuss the arbitration until there is a resolution. Based on the stage of arbitration, and review of the current facts and circumstances, we do not believe there is a reasonable possibility of a loss that might result from an adverse judgment or a settlement of this case.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">General Medicine Action&#8212;</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On August&#160;16, 2004, General Medicine, P.C. filed a lawsuit against us captioned </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">General Medicine, P.C. v. HealthSouth Corp.</font><font style="font-family:inherit;font-size:10pt;"> seeking the recovery of allegedly fraudulent transfers involving assets of Horizon/CMS Healthcare Corporation, a former subsidiary of HealthSouth. The lawsuit is pending in the Circuit Court of Jefferson County, Alabama (the &#8220;Alabama Action&#8221;).</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General Medicine's underlying claim against Horizon/CMS originates from a services contract entered into in 1995 between General Medicine and Horizon/CMS whereby General Medicine agreed to provide medical director services to skilled nursing facilities owned by Horizon/CMS for a term of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three years</font><font style="font-family:inherit;font-size:10pt;">. Horizon/CMS terminated the agreement for cause six months after it was executed, and General Medicine then initiated a lawsuit against Horizon/CMS in the United States District Court for the Eastern District of Michigan in 1996 (the &#8220;Michigan Action&#8221;). General Medicine's complaint in the Michigan Action alleged that Horizon/CMS breached the services contract by wrongfully terminating General Medicine. We acquired Horizon/CMS in 1997 and sold it to Meadowbrook Healthcare, Inc. in 2001 pursuant to a stock purchase agreement. In 2004, Meadowbrook, without the knowledge of HealthSouth, consented to the entry of a final judgment in the Michigan Action in favor of General Medicine against Horizon/CMS for the alleged wrongful termination of the contract with General Medicine in the amount of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$376 million</font><font style="font-family:inherit;font-size:10pt;">, plus interest from the date of the judgment until paid at the rate of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">10%</font><font style="font-family:inherit;font-size:10pt;"> per annum (the &#8220;Consent Judgment&#8221;). The </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$376 million</font><font style="font-family:inherit;font-size:10pt;"> damages figure was unilaterally selected by General Medicine and was not tested or opposed by Meadowbrook. Additionally, the settlement agreement (the &#8220;Settlement&#8221;) used as the basis for the Consent Judgment provided that Meadowbrook would pay only </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$300,000</font><font style="font-family:inherit;font-size:10pt;"> to General Medicine to settle the Michigan Action and that General Medicine would seek to recover the remaining balance of the Consent Judgment solely from us. We were not a party to the Michigan Action, the Settlement negotiated by Meadowbrook, or the Consent Judgment. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The complaint filed by General Medicine against us in the Alabama Action alleges that while Horizon/CMS was our wholly owned subsidiary, General Medicine was an existing creditor of Horizon/CMS by virtue of the Settlement. The complaint also alleges we caused Horizon/CMS to transfer its assets to us for less than a reasonably equivalent value or, in the alternative, with the actual intent to defraud creditors of Horizon/CMS, including General Medicine, in violation of the Alabama Uniform Fraudulent Transfer Act. General Medicine further alleges in its amended complaint that we are liable for the Consent Judgment despite not being a party to it because as Horizon/CMS's parent we failed to observe corporate formalities in our operation and ownership of Horizon/CMS, misused our control of Horizon/CMS, stripped assets from Horizon/CMS, and engaged in other conduct which amounted to a fraud on Horizon/CMS's creditors. General Medicine has requested relief including recovery of the unpaid amount of the Consent Judgment, the avoidance of the subject transfers of assets, attachment of the assets transferred to us, appointment of a receiver over the transferred properties, and a monetary judgment for the value of properties transferred. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have denied liability to General Medicine and asserted counterclaims against General Medicine for fraud, injurious falsehood, tortious interference with business relations, conspiracy, unjust enrichment, abuse of process, and other causes of action. In our counterclaims, we alleged the Consent Judgment is the product of fraud, collusion and bad faith by General Medicine and Meadowbrook and, further, that these parties were guilty of a conspiracy to manufacture a lawsuit against HealthSouth in favor of General Medicine. Consequently, we assert that the Consent Judgment is not evidence of a legitimate debt owed by Horizon/CMS to General Medicine that is collectible from HealthSouth under any theory of liability.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2008, after we obtained discovery concerning the circumstances that lead to the entry of the Consent Judgment, we filed a motion in the Michigan Action asking the court to set aside the Consent Judgment on grounds that it was the product of fraud on the court and collusion by the parties. On May 21, 2009, the court granted our motion to set aside the Consent Judgment on grounds that it was the product of fraud on the court. On March 9, 2010, General Medicine filed an appeal of the court's decision to the Sixth Circuit Court of Appeals. The parties agreed to a voluntary stay of the Alabama Action pending the outcome of General Medicine's appeal to the Sixth Circuit Court of Appeals. On April 10, 2012, a three-judge panel of the Sixth Circuit Court of Appeals reversed the lower court's ruling and reinstated the Consent Judgment. On June 26, 2012, the Sixth Circuit Court of Appeals denied our application for rehearing by the full court. Due to the conclusion of the appeal in the Michigan Action, General Medicine has requested the Circuit Court of Jefferson County, Alabama to reactivate the Alabama Action.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on the stage of litigation, review of the current facts and circumstances as we understand them, the nature of the underlying claim, the results of the proceedings to date, and the nature and scope of the defense we continue to mount, we do not believe an adverse judgment or settlement is probable in this matter, and it is also not possible to estimate the amount of loss, if any, or range of possible loss that might result from an adverse judgment or settlement of this case. We intend to vigorously defend ourselves against General Medicine's claims and to vigorously prosecute our counterclaims against General Medicine.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other Litigation&#8212;</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have been named as a defendant in a lawsuit filed March 28, 2003 by several individual stockholders in the Circuit Court of Jefferson County, Alabama, captioned </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Nichols v. HealthSouth Corp</font><font style="font-family:inherit;font-size:10pt;">. The plaintiffs allege that we, some of our former officers, and our former investment bank engaged in a scheme to overstate and misrepresent our earnings and financial position. The plaintiffs are seeking compensatory and punitive damages. This case was consolidated with the </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Tucker</font><font style="font-family:inherit;font-size:10pt;"> case for discovery and other pretrial purposes and was stayed in the Circuit Court on August&#160;8, 2005. The plaintiffs filed an amended complaint on November 9, 2010 to which we responded with a motion to dismiss filed on December 22, 2010. During a hearing on February&#160;24, 2012, plaintiffs' counsel indicated his intent to dismiss certain claims against us. Instead, on March 9, 2012, the plaintiffs amended their complaint to include additional securities fraud claims against HealthSouth and add several former officers to the lawsuit. One of those named officers removed the case to federal court on March 14, 2012. We filed a motion to remand the case on April 10, 2012. We intend to vigorously defend ourselves in this case. Based on the stage of litigation, review of the current facts and circumstances as we understand them, the nature of the underlying claim, the results of the proceedings to date, and the nature and scope of the defense we continue to mount, we do not believe an adverse judgment or settlement is probable in this matter, and it is also not possible to estimate the amount of loss, if any, or range of possible loss that might result from an adverse judgment or settlement of this case. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We were named as a defendant in a lawsuit filed March 3, 2009 by an individual in the Court of Common Pleas, Richland County, South Carolina, captioned </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Sulton v. HealthSouth Corp, et al.</font><font style="font-family:inherit;font-size:10pt;"> The plaintiff alleged that certain treatment he received at a HealthSouth facility complicated a pre-existing infectious injury. The plaintiff sought recovery for pain and suffering, medical expenses, punitive damages, and other damages. On July 30, 2010, the jury in this case returned a verdict in favor of the plaintiff for </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$12.3 million</font><font style="font-family:inherit;font-size:10pt;"> in damages. On May 2, 2011, we filed our brief in the appeal of this verdict with the South Carolina Court of Appeals. On May 29, 2012, the Supreme Court of South Carolina granted the parties' joint motion to submit the appeal directly to that court. The parties have completed their briefing for the appeal, but oral argument has not yet been scheduled. We intend to vigorously defend ourselves in this case. We believe the attending nurses acted both responsibly and professionally, and we will continue to support and defend them. Although we continue to believe in the merit of our defenses and counterarguments, we have recorded a liability of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$12.3 million</font><font style="font-family:inherit;font-size:10pt;"> in </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other current liabilities</font><font style="font-family:inherit;font-size:10pt;"> in our condensed consolidated balance sheets as of June 30, 2012 and December 31, 2011 with a corresponding receivable of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$7.7 million</font><font style="font-family:inherit;font-size:10pt;"> in </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other current assets</font><font style="font-family:inherit;font-size:10pt;"> for the portion of the claim we expect to be covered through our excess insurance coverages, resulting in a net charge of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$4.6 million</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other operating expenses</font><font style="font-family:inherit;font-size:10pt;"> in our consolidated statement of operations for the year ended December 31, 2010. The </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$4.6 million</font><font style="font-family:inherit;font-size:10pt;"> portion of this claim would be a covered claim through our captive insurance subsidiary, HCS, Ltd. As a result of the verdict, we made a </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$6.0 million</font><font style="font-family:inherit;font-size:10pt;"> payment through HCS, Ltd. to the Richland County Clerk as a deposit during the on-going appeal process. The deposit is a restricted asset included in O</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">ther current assets</font><font style="font-family:inherit;font-size:10pt;"> in our condensed consolidated balance sheets as of June 30, 2012 and December 31, 2011.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On May 31, 2012, we joined in a settlement of the previously disclosed dispute between Washington Regional Rehabilitation Services, LLC, our partner in a joint venture hospital in Fayetteville, Arkansas, and that hospital's landlord, an affiliate of Medical Properties Trust, over whether Washington Regional properly exercised its right to purchase the property under the related lease. The related case was originally filed February&#160;4, 2011 in the United States District Court for the Western District of Arkansas and captioned </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Washington Regional Outreach Services v. MPT of Fayetteville, LLC</font><font style="font-family:inherit;font-size:10pt;">. With this litigation pending, the lease expired on June 30, 2011. Subsequent to that date, we were joined to the suit as a necessary party. Under the settlement agreement, the joint venture acquired the hospital from MPT on June 15, 2012. In exchange for the hospital and to settle all pending litigation, MPT received approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$16 million</font><font style="font-family:inherit;font-size:10pt;"> in cash as well as the lease payments held in escrow during the dispute. Accordingly, each party agreed to release all claims related to the litigation, and the court dismissed the litigation with prejudice on June 15, 2012 upon joint petition by the parties.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other Matters&#8212;</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The False Claims Act, 18 U.S.C. &#167; 287, allows private citizens, called &#8220;relators,&#8221; to institute civil proceedings alleging violations of the False Claims Act. These </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">qui tam</font><font style="font-family:inherit;font-size:10pt;"> cases are generally sealed by the court at the time of filing. The only parties privy to the information contained in the complaint are the relator, the federal government, and the presiding court. It is possible that </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">qui tam</font><font style="font-family:inherit;font-size:10pt;"> lawsuits have been filed against us and that we are unaware of such filings or have been ordered by the presiding court not to discuss or disclose the filing of such lawsuits. We may be subject to liability under one or more undisclosed </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">qui tam</font><font style="font-family:inherit;font-size:10pt;"> cases brought pursuant to the False Claims Act.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">It is our obligation as a participant in Medicare and other federal healthcare programs to routinely conduct audits and reviews of the accuracy of our billing systems and other regulatory compliance matters. As a result of these reviews, we have made, and will continue to make, disclosures to the HHS-OIG and CMS relating to amounts we suspect represent over-payments from these programs, whether due to inaccurate billing or otherwise. Some of these disclosures have resulted in, or may result in, HealthSouth refunding amounts to Medicare or other federal healthcare programs. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 24, 2011, we received a document subpoena addressed to HealthSouth Hospital of Houston, a long-term acute care hospital ("LTCH") we closed in August 2011, from the Dallas, Texas office of the HHS-OIG. The subpoena is in connection with an investigation of possible false or otherwise improper claims submitted to Medicare and Medicaid and requests documents and materials relating to this closed LTCH's patient admissions, length of stay, and discharge matters. We are cooperating fully with the HHS-OIG in connection with this subpoena and are currently unable to predict the timing or outcome of this investigation. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We also face certain financial risks and challenges relating to our 2007 divestiture transactions (see Note&#160;18, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Assets and Liabilities in and Results of Discontinued Operations</font><font style="font-family:inherit;font-size:10pt;">, to the consolidated financial statements accompanying the 2011 Form 10-K) following their closing. These include indemnification obligations or other claims and assessments, which in the aggregate could have a material adverse effect on our financial position, results of operations, and cash flows.</font></div></div>
us-gaap Management Fees Revenue
ManagementFeesRevenue
0 USD
CY2012Q2 us-gaap Management Fees Revenue
ManagementFeesRevenue
0 USD
us-gaap Management Fees Revenue
ManagementFeesRevenue
0 USD
CY2011Q2 us-gaap Management Fees Revenue
ManagementFeesRevenue
0 USD
CY2012Q2 us-gaap Minority Interest
MinorityInterest
97900000 USD
CY2011Q4 us-gaap Minority Interest
MinorityInterest
84600000 USD
us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
20500000 USD
us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
20200000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-95600000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-97000000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-88300000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-49200000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
158100000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
195000000 USD
CY2012Q2 us-gaap Net Income Loss
NetIncomeLoss
46700000 USD
CY2011Q2 us-gaap Net Income Loss
NetIncomeLoss
21900000 USD
us-gaap Net Income Loss
NetIncomeLoss
101700000 USD
us-gaap Net Income Loss
NetIncomeLoss
90900000 USD
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
22100000 USD
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
25800000 USD
CY2011Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
10400000 USD
CY2012Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
13200000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
88700000 USD
CY2011Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
15400000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
77700000 USD
CY2012Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
40400000 USD
CY2012Q2 us-gaap Other Assets Current
OtherAssetsCurrent
137700000 USD
CY2011Q4 us-gaap Other Assets Current
OtherAssetsCurrent
138100000 USD
CY2011Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
128300000 USD
us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
146300000 USD
CY2011Q2 us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
75400000 USD
CY2012Q2 us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
74400000 USD
us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
147400000 USD
CY2012Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
128800000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax Period Increase Decrease
OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecrease
400000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax Period Increase Decrease
OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecrease
1000000 USD
CY2012Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Period Increase Decrease
OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecrease
200000 USD
CY2011Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Period Increase Decrease
OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecrease
200000 USD
us-gaap Other Comprehensive Income Reclassification Adjustment For Sale Of Securities Included In Net Income Net Of Tax
OtherComprehensiveIncomeReclassificationAdjustmentForSaleOfSecuritiesIncludedInNetIncomeNetOfTax
500000 USD
CY2012Q2 us-gaap Other Comprehensive Income Reclassification Adjustment For Sale Of Securities Included In Net Income Net Of Tax
OtherComprehensiveIncomeReclassificationAdjustmentForSaleOfSecuritiesIncludedInNetIncomeNetOfTax
0 USD
CY2011Q2 us-gaap Other Comprehensive Income Reclassification Adjustment For Sale Of Securities Included In Net Income Net Of Tax
OtherComprehensiveIncomeReclassificationAdjustmentForSaleOfSecuritiesIncludedInNetIncomeNetOfTax
0 USD
us-gaap Other Comprehensive Income Reclassification Adjustment For Sale Of Securities Included In Net Income Net Of Tax
OtherComprehensiveIncomeReclassificationAdjustmentForSaleOfSecuritiesIncludedInNetIncomeNetOfTax
0 USD
CY2011Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
200000 USD
CY2012Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
200000 USD
hls Provision For Government Class Action And Related Settlements Expense
ProvisionForGovernmentClassActionAndRelatedSettlementsExpense
0 USD
CY2012Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
265000000 USD
CY2011Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
267800000 USD
CY2012Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
135800000 USD
CY2011Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
133200000 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-3000000 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-3000000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1300000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1300000 USD
CY2011Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
700000 USD
CY2012Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
400000 USD
us-gaap Partners Capital Account Contributions
PartnersCapitalAccountContributions
9800000 USD
us-gaap Payments For Proceeds From Derivative Instrument Investing Activities
PaymentsForProceedsFromDerivativeInstrumentInvestingActivities
10900000 USD
us-gaap Payments For Proceeds From Derivative Instrument Investing Activities
PaymentsForProceedsFromDerivativeInstrumentInvestingActivities
0 USD
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
-100000 USD
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
1800000 USD
us-gaap Payments For Repurchase Of Convertible Preferred Stock
PaymentsForRepurchaseOfConvertiblePreferredStock
0 USD
us-gaap Payments For Repurchase Of Convertible Preferred Stock
PaymentsForRepurchaseOfConvertiblePreferredStock
46000000 USD
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
4200000 USD
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
0 USD
us-gaap Payments Of Dividends Minority Interest
PaymentsOfDividendsMinorityInterest
23300000 USD
us-gaap Payments Of Dividends Minority Interest
PaymentsOfDividendsMinorityInterest
24000000 USD
us-gaap Payments Of Dividends Preferred Stock And Preference Stock
PaymentsOfDividendsPreferredStockAndPreferenceStock
13100000 USD
us-gaap Payments Of Dividends Preferred Stock And Preference Stock
PaymentsOfDividendsPreferredStockAndPreferenceStock
13000000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
31700000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
82800000 USD
us-gaap Payments To Acquire Restricted Investments
PaymentsToAcquireRestrictedInvestments
4400000 USD
us-gaap Payments To Acquire Restricted Investments
PaymentsToAcquireRestrictedInvestments
7900000 USD
us-gaap Proceeds From Contributions From Affiliates
ProceedsFromContributionsFromAffiliates
7900000 USD
us-gaap Proceeds From Contributions From Affiliates
ProceedsFromContributionsFromAffiliates
0 USD
us-gaap Proceeds From Issuance Of Secured Debt
ProceedsFromIssuanceOfSecuredDebt
100000000 USD
us-gaap Proceeds From Issuance Of Secured Debt
ProceedsFromIssuanceOfSecuredDebt
0 USD
us-gaap Proceeds From Issuance Of Senior Long Term Debt
ProceedsFromIssuanceOfSeniorLongTermDebt
0 USD
us-gaap Proceeds From Issuance Of Senior Long Term Debt
ProceedsFromIssuanceOfSeniorLongTermDebt
120000000 USD
us-gaap Proceeds From Long Term Lines Of Credit
ProceedsFromLongTermLinesOfCredit
190000000 USD
us-gaap Proceeds From Long Term Lines Of Credit
ProceedsFromLongTermLinesOfCredit
40000000 USD
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
4200000 USD
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
0 USD
us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
0 USD
us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
0 USD
CY2011Q2 us-gaap Profit Loss
ProfitLoss
32300000 USD
CY2012Q2 us-gaap Profit Loss
ProfitLoss
59900000 USD
us-gaap Profit Loss
ProfitLoss
116700000 USD
us-gaap Profit Loss
ProfitLoss
123800000 USD
CY2012Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
718900000 USD
CY2011Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
664400000 USD
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
9800000 USD
dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
Yes
CY2011Q2 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
5000000 USD
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
12800000 USD
CY2012Q2 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
6500000 USD
us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
5700000 USD
us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
6800000 USD
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
335900000 USD
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
4700000 USD
us-gaap Repayments Of Long Term Lines Of Credit
RepaymentsOfLongTermLinesOfCredit
50000000 USD
us-gaap Repayments Of Long Term Lines Of Credit
RepaymentsOfLongTermLinesOfCredit
128000000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
9500000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
12000000 USD
CY2012Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
200000 shares
CY2012Q2 us-gaap Significant Change In Unrecognized Tax Benefits Is Reasonably Possible Amount Of Unrecorded Benefit
SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit
500000 USD
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4400000 USD
CY2012Q2 us-gaap Stockholders Equity
StockholdersEquity
195800000 USD
CY2011Q4 us-gaap Stockholders Equity
StockholdersEquity
117000000 USD
CY2011Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
201600000 USD
CY2012Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
293700000 USD
CY2011Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
96600000 USD
CY2010Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-2200000 USD
us-gaap Stockholders Equity Other
StockholdersEquityOther
-2600000 USD
us-gaap Stockholders Equity Other
StockholdersEquityOther
-1800000 USD
CY2011Q2 us-gaap Supplies Expense
SuppliesExpense
26200000 USD
us-gaap Supplies Expense
SuppliesExpense
52000000 USD
CY2012Q2 us-gaap Supplies Expense
SuppliesExpense
25900000 USD
us-gaap Supplies Expense
SuppliesExpense
52400000 USD
CY2011Q4 us-gaap Temporary Equity Carrying Amount
TemporaryEquityCarryingAmount
387400000 USD
CY2012Q2 us-gaap Temporary Equity Carrying Amount
TemporaryEquityCarryingAmount
342200000 USD
CY2012Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
79500000 USD
CY2011Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
6000000 USD
us-gaap Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities
UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
-600000 USD
CY2012Q2 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
100000 USD
CY2011Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
100000 USD
us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
74100000 USD
CY2012Q2 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
13400000 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
16100000 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
13800000 shares
CY2011Q2 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
16200000 shares
CY2012Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
108000000 shares
CY2011Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
109500000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
108300000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
109300000 shares
CY2012Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
94600000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
93200000 shares
CY2011Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
93300000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
94500000 shares
CY2011Q2 hls Cash And Cash Equivalents Of Facilities In Discontinued Operations Ending Balance
CashAndCashEquivalentsOfFacilitiesInDiscontinuedOperationsEndingBalance
0 USD
CY2012Q2 hls Cash And Cash Equivalents Of Facilities In Discontinued Operations Ending Balance
CashAndCashEquivalentsOfFacilitiesInDiscontinuedOperationsEndingBalance
-100000 USD
CY2012Q2 hls Cash And Cash Equivalents Of Facilities In Discontinuted Operations Beginning Balance
CashAndCashEquivalentsOfFacilitiesInDiscontinutedOperationsBeginningBalance
0 USD
CY2011Q2 hls Cash And Cash Equivalents Of Facilities In Discontinuted Operations Beginning Balance
CashAndCashEquivalentsOfFacilitiesInDiscontinutedOperationsBeginningBalance
100000 USD
hls Estimated Effective Blended Federal And State Income Tax Rate
EstimatedEffectiveBlendedFederalAndStateIncomeTaxRate
0.39
CY2012Q2 hls Estimated Effective Blended Federal And State Income Tax Rate
EstimatedEffectiveBlendedFederalAndStateIncomeTaxRate
0.390
dei Entity Central Index Key
EntityCentralIndexKey
0000785161
CY2012Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
95661302 shares
CY2012Q2 hls Excess Tax Benefits From Share Based Compensation
ExcessTaxBenefitsFromShareBasedCompensation
8300000 USD
hls Government Class Action And Related Settlements Cf
GovernmentClassActionAndRelatedSettlementsCf
0 USD
hls Government Class Action And Related Settlements Cf
GovernmentClassActionAndRelatedSettlementsCf
6500000 USD
hls Equity In Net Income Of Consolidated Affiliates
EquityInNetIncomeOfConsolidatedAffiliates
0 USD
CY2012Q2 hls Equity In Net Income Of Consolidated Affiliates
EquityInNetIncomeOfConsolidatedAffiliates
0 USD
hls Equity In Net Income Of Consolidated Affiliates
EquityInNetIncomeOfConsolidatedAffiliates
0 USD
CY2011Q2 hls Equity In Net Income Of Consolidated Affiliates
EquityInNetIncomeOfConsolidatedAffiliates
0 USD
CY2011Q2 hls Equity Method Investment Summarized Financial Information Operating Expenses
EquityMethodInvestmentSummarizedFinancialInformationOperatingExpenses
-12700000 USD
hls Equity Method Investment Summarized Financial Information Operating Expenses
EquityMethodInvestmentSummarizedFinancialInformationOperatingExpenses
-25800000 USD
CY2012Q2 hls Equity Method Investment Summarized Financial Information Operating Expenses
EquityMethodInvestmentSummarizedFinancialInformationOperatingExpenses
-13800000 USD
hls Equity Method Investment Summarized Financial Information Operating Expenses
EquityMethodInvestmentSummarizedFinancialInformationOperatingExpenses
-27900000 USD
CY2011Q2 hls Estimated Effective Blended Federal And State Income Tax Rate
EstimatedEffectiveBlendedFederalAndStateIncomeTaxRate
0.39
hls Estimated Effective Blended Federal And State Income Tax Rate
EstimatedEffectiveBlendedFederalAndStateIncomeTaxRate
0.39
hls Government Class Action And Related Settlements Expense
GovernmentClassActionAndRelatedSettlementsExpense
-10600000 USD
CY2012Q2 hls Government Class Action And Related Settlements Expense
GovernmentClassActionAndRelatedSettlementsExpense
0 USD
hls Government Class Action And Related Settlements Expense
GovernmentClassActionAndRelatedSettlementsExpense
0 USD
CY2011Q2 hls Government Class Action And Related Settlements Expense
GovernmentClassActionAndRelatedSettlementsExpense
-10600000 USD
CY2012Q2 hls Guarantees Maximum Term
GuaranteesMaximumTerm
84
CY2012Q2 hls Guarantees Minimum Term
GuaranteesMinimumTerm
1
hls Income Loss From Continuing Operations Attributable To Common Shareholders Basic
IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic
74600000 USD
CY2011Q2 hls Income Loss From Continuing Operations Attributable To Common Shareholders Basic
IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic
12900000 USD
CY2012Q2 hls Income Loss From Continuing Operations Attributable To Common Shareholders Basic
IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic
36900000 USD
hls Income Loss From Continuing Operations Attributable To Common Shareholders Basic
IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic
68600000 USD
hls Income Loss From Continuing Operations Before Income Tax Benefit Expense
IncomeLossFromContinuingOperationsBeforeIncomeTaxBenefitExpense
108500000 USD
CY2011Q2 hls Income Loss From Continuing Operations Before Income Tax Benefit Expense
IncomeLossFromContinuingOperationsBeforeIncomeTaxBenefitExpense
41900000 USD
CY2012Q2 hls Income Loss From Continuing Operations Before Income Tax Benefit Expense
IncomeLossFromContinuingOperationsBeforeIncomeTaxBenefitExpense
83300000 USD
hls Income Loss From Continuing Operations Before Income Tax Benefit Expense
IncomeLossFromContinuingOperationsBeforeIncomeTaxBenefitExpense
169600000 USD
hls Income Tax Benefit Resulting From Reduction In Unrecognized Tax Benefits
IncomeTaxBenefitResultingFromReductionInUnrecognizedTaxBenefits
-5000000 USD
hls Income Tax Benefit Resulting From Tax Settlement
IncomeTaxBenefitResultingFromTaxSettlement
-24000000 USD
CY2011Q2 hls Income Tax Expense Resulting From Application Of Blended Federal And State Rate
IncomeTaxExpenseResultingFromApplicationOfBlendedFederalAndStateRate
12000000 USD
hls Income Tax Expense Resulting From Application Of Blended Federal And State Rate
IncomeTaxExpenseResultingFromApplicationOfBlendedFederalAndStateRate
33000000 USD
hls Increase Decrease In Refunds Due Patients And Other Third Party Payors
IncreaseDecreaseInRefundsDuePatientsAndOtherThirdPartyPayors
4300000 USD
hls Increase Decrease In Refunds Due Patients And Other Third Party Payors
IncreaseDecreaseInRefundsDuePatientsAndOtherThirdPartyPayors
-16700000 USD
CY2012Q2 hls Initial Suspension Period Medicare Payments
InitialSuspensionPeriodMedicarePayments
180 D
CY2012Q2 hls Medicare Denials Percentage Collected After Appeal
MedicareDenialsPercentageCollectedAfterAppeal
0.58
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2012Q2 hls Net Operating Revenues Less Provision For Doubtful Accounts
NetOperatingRevenuesLessProvisionForDoubtfulAccounts
526900000 USD
hls Net Operating Revenues Less Provision For Doubtful Accounts
NetOperatingRevenuesLessProvisionForDoubtfulAccounts
1001300000 USD
hls Net Operating Revenues Less Provision For Doubtful Accounts
NetOperatingRevenuesLessProvisionForDoubtfulAccounts
1059200000 USD
CY2011Q2 hls Net Operating Revenues Less Provision For Doubtful Accounts
NetOperatingRevenuesLessProvisionForDoubtfulAccounts
500100000 USD
CY2011Q2 hls Percentage Of Net Operating Revenues Medicare
PercentageOfNetOperatingRevenuesMedicare
0.720
CY2012Q2 hls Percentage Of Net Operating Revenues Other Income
PercentageOfNetOperatingRevenuesOtherIncome
0.016
CY2012Q2 hls Number Of General Or Limited Partnerships Limited Liability Companies Or Joint Ventures
NumberOfGeneralOrLimitedPartnershipsLimitedLiabilityCompaniesOrJointVentures
9 facilities
CY2012Q2 hls Number Of Guarantees
NumberOfGuarantees
14
CY2012Q2 hls Number Of Partially Owned Subsidiaries Nonconsolidated
NumberOfPartiallyOwnedSubsidiariesNonconsolidated
13 facilities
hls Occupancy Cost
OccupancyCost
24800000 USD
hls Occupancy Cost
OccupancyCost
23700000 USD
CY2011Q2 hls Occupancy Cost
OccupancyCost
12100000 USD
CY2012Q2 hls Occupancy Cost
OccupancyCost
12300000 USD
hls Ownership Percentage Of Subsidiary Guarantors
OwnershipPercentageOfSubsidiaryGuarantors
1.00
hls Percentage Of Net Operating Revenues Managed Care
PercentageOfNetOperatingRevenuesManagedCare
0.198
hls Percentage Of Net Operating Revenues Managed Care
PercentageOfNetOperatingRevenuesManagedCare
0.195
CY2012Q2 hls Percentage Of Net Operating Revenues Managed Care
PercentageOfNetOperatingRevenuesManagedCare
0.196
CY2011Q2 hls Percentage Of Net Operating Revenues Managed Care
PercentageOfNetOperatingRevenuesManagedCare
0.198
CY2011Q2 hls Percentage Of Net Operating Revenues Medicaid
PercentageOfNetOperatingRevenuesMedicaid
0.018
hls Percentage Of Net Operating Revenues Medicaid
PercentageOfNetOperatingRevenuesMedicaid
0.017
hls Percentage Of Net Operating Revenues Medicaid
PercentageOfNetOperatingRevenuesMedicaid
0.012
CY2012Q2 hls Percentage Of Net Operating Revenues Medicaid
PercentageOfNetOperatingRevenuesMedicaid
0.013
CY2012Q2 hls Percentage Of Net Operating Revenues Medicare
PercentageOfNetOperatingRevenuesMedicare
0.729
hls Percentage Of Net Operating Revenues Medicare
PercentageOfNetOperatingRevenuesMedicare
0.733
hls Percentage Of Net Operating Revenues Medicare
PercentageOfNetOperatingRevenuesMedicare
0.717
CY2011Q2 hls Percentage Of Net Operating Revenues Other Income
PercentageOfNetOperatingRevenuesOtherIncome
0.016
hls Percentage Of Net Operating Revenues Other Income
PercentageOfNetOperatingRevenuesOtherIncome
0.015
hls Percentage Of Net Operating Revenues Other Income
PercentageOfNetOperatingRevenuesOtherIncome
0.019
CY2011Q2 hls Percentage Of Net Operating Revenues Other Third Party Payors
PercentageOfNetOperatingRevenuesOtherThirdPartyPayors
0.020
hls Percentage Of Net Operating Revenues Other Third Party Payors
PercentageOfNetOperatingRevenuesOtherThirdPartyPayors
0.021
CY2012Q2 hls Percentage Of Net Operating Revenues Other Third Party Payors
PercentageOfNetOperatingRevenuesOtherThirdPartyPayors
0.018
hls Percentage Of Net Operating Revenues Other Third Party Payors
PercentageOfNetOperatingRevenuesOtherThirdPartyPayors
0.017
hls Percentage Of Net Operating Revenues Patients
PercentageOfNetOperatingRevenuesPatients
0.013
hls Percentage Of Net Operating Revenues Patients
PercentageOfNetOperatingRevenuesPatients
0.011
CY2012Q2 hls Percentage Of Net Operating Revenues Patients
PercentageOfNetOperatingRevenuesPatients
0.013
CY2011Q2 hls Percentage Of Net Operating Revenues Patients
PercentageOfNetOperatingRevenuesPatients
0.011
CY2012Q2 hls Percentage Of Net Operating Revenues Total
PercentageOfNetOperatingRevenuesTotal
1.000
hls Percentage Of Net Operating Revenues Total
PercentageOfNetOperatingRevenuesTotal
1.000
hls Percentage Of Net Operating Revenues Total
PercentageOfNetOperatingRevenuesTotal
1.000
CY2011Q2 hls Percentage Of Net Operating Revenues Total
PercentageOfNetOperatingRevenuesTotal
1.000
hls Percentage Of Net Operating Revenues Workers Compensation
PercentageOfNetOperatingRevenuesWorkersCompensation
0.015
CY2012Q2 hls Percentage Of Net Operating Revenues Workers Compensation
PercentageOfNetOperatingRevenuesWorkersCompensation
0.015
CY2011Q2 hls Percentage Of Net Operating Revenues Workers Compensation
PercentageOfNetOperatingRevenuesWorkersCompensation
0.017
hls Percentage Of Net Operating Revenues Workers Compensation
PercentageOfNetOperatingRevenuesWorkersCompensation
0.017
hls Premium Paid On Redemption Of Bonds
PremiumPaidOnRedemptionOfBonds
0 USD
hls Premium Paid On Redemption Of Bonds
PremiumPaidOnRedemptionOfBonds
18000000 USD
hls Premium Received On Bond Issuance
PremiumReceivedOnBondIssuance
0 USD
hls Premium Received On Bond Issuance
PremiumReceivedOnBondIssuance
4100000 USD
hls Professional Fees Accounting Tax And Legal
ProfessionalFeesAccountingTaxAndLegal
9100000 USD
CY2012Q2 hls Professional Fees Accounting Tax And Legal
ProfessionalFeesAccountingTaxAndLegal
5500000 USD
CY2011Q2 hls Professional Fees Accounting Tax And Legal
ProfessionalFeesAccountingTaxAndLegal
8400000 USD
hls Professional Fees Accounting Tax And Legal
ProfessionalFeesAccountingTaxAndLegal
12200000 USD
hls Provision For Government Class Action And Related Settlements Expense
ProvisionForGovernmentClassActionAndRelatedSettlementsExpense
-10600000 USD
hls Repurchase Of Convertible Perpetual Preferred Stock
RepurchaseOfConvertiblePerpetualPreferredStock
0 USD
CY2012Q2 hls Repurchase Of Convertible Perpetual Preferred Stock
RepurchaseOfConvertiblePerpetualPreferredStock
300000 USD
hls Repurchase Of Convertible Perpetual Preferred Stock
RepurchaseOfConvertiblePerpetualPreferredStock
800000 USD
CY2011Q2 hls Repurchase Of Convertible Perpetual Preferred Stock
RepurchaseOfConvertiblePerpetualPreferredStock
0 USD
CY2012Q2 hls Salaries And Benefits
SalariesAndBenefits
257400000 USD
hls Salaries And Benefits
SalariesAndBenefits
485600000 USD
CY2011Q2 hls Salaries And Benefits
SalariesAndBenefits
241600000 USD
hls Salaries And Benefits
SalariesAndBenefits
518400000 USD
CY2012Q2 hls Share Based Compensation Equity Instruments Other Than Options Issued In Period
ShareBasedCompensationEquityInstrumentsOtherThanOptionsIssuedInPeriod
200000 shares
CY2012Q1 hls Share Based Compensation Equity Instruments Other Than Options Issued In Period
ShareBasedCompensationEquityInstrumentsOtherThanOptionsIssuedInPeriod
900000 shares
hls Share Based Compensation Equity Instruments Other Than Options Service Requirement Only Issued In Period
ShareBasedCompensationEquityInstrumentsOtherThanOptionsServiceRequirementOnlyIssuedInPeriod
600000 shares
hls Treasury Stock Reacquired
TreasuryStockReacquired
11900000 USD
hls Treasury Stock Reacquired
TreasuryStockReacquired
4300000 USD
hls Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued Decreases Resulting From Settlements With Taxing Authorities
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccruedDecreasesResultingFromSettlementsWithTaxingAuthorities
0 USD
hls Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccruedIncreasesResultingFromPriorPeriodTaxPositions
0 USD
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2012
dei Document Period End Date
DocumentPeriodEndDate
2012-06-30
dei Document Type
DocumentType
10-Q
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2011Q2 dei Entity Public Float
EntityPublicFloat
2500000000 USD
dei Entity Registrant Name
EntityRegistrantName
HEALTHSOUTH CORP

Files In Submission

Name View Source Status
0000785161-12-000039-index-headers.html Edgar Link pending
0000785161-12-000039-index.html Edgar Link pending
0000785161-12-000039.txt Edgar Link pending
0000785161-12-000039-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
hls-20120630.xml Edgar Link completed
hls-20120630.xsd Edgar Link pending
hls-20120630_cal.xml Edgar Link unprocessable
hls-20120630_def.xml Edgar Link unprocessable
hls-20120630_lab.xml Edgar Link unprocessable
hls-20120630_pre.xml Edgar Link unprocessable
hls10q63012.htm Edgar Link pending
hls10q63012ex311.htm Edgar Link pending
hls10q63012ex312.htm Edgar Link pending
hls10q63012ex321.htm Edgar Link pending
hls10q63012ex322.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending